Background: Pancreatic Stone Protein (PSP) is a protein naturally produced mainly in the pancreas and the gut. There is evidence from experimental and clinical trials that blood PSP levels rise in the presence of inflammation or infection. However, it is not known whether PSP is superior to other established blood tests (e.g. White Blood Count, Neutrophils or C -reactive protein) in predicting appendicitis in patients presenting with abdominal pain and a clinical suspicion of appendicitis at the emergency room.
Background
Appendicitis is defined as an inflammation of the vermiform appendix and is a common condition and an urgent surgical illness. It is one of the most common causes of acute abdominal pain and remains a diagnostic challenge. It has variable manifestations and generous overlap with other clinical syndromes. In fact morbidity increases significantly with the diagnostic delay and left untreated, appendicitis has the potential for severe complications, including perforation or sepsis, and may even cause death. Despite diagnostic and therapeutic advancement in medicine, appendicitis still remains a clinical emergency [1] .
No single sign, symptom, or diagnostic test exists which accurately confirms an appendiceal inflammation. The classic history of anorexia and periumbilical pain followed by nausea, right lower quadrant (RLQ) pain, and vomiting occurs in only 50% of cases [1, 2] .
Accepted etiologic factors of appendicitis are appendiceal lumen obstruction and infection. The main therapeutic option still remains the surgical removal of the vermiform appendix even though a few studies promote an antibiotic treatment [3] . After admission to the emergency department (ED), patients presenting with abdominal pain caused by a variety of different etiologic factors have to be worked up with the goal of approaching 100% sensitivity for the diagnosis in a time-, cost-, and consultation-efficient manner [4] .
It is reported that appendectomy carries a complication rate of up to 15%, as well as increased associated costs and the discomfort of hospitalisation and surgery [5] . Delay in diagnosis and treatment account for much of the associated mortality and morbidity. Therefore, the goal of the surgeon is to diagnose appendicitis as early as possible.
The overall mortality rate of 0.2 -0.8% is attributable to complications of the disease rather than to surgical interventions [2] . The mortality rate in children ranges from 0.1% to 1%; in patients older than 70 years, the rate rises above 20%, primarily because of diagnostic and therapeutic delay [4, 6] .
Appendiceal perforation is associated with increased morbidity and mortality compared with non-perforating appendicitis. The mortality risk of acute but not gangrenous appendicitis is less than 0.1%, but the risk rises to 0.6% in gangrenous appendicitis. The rate of perforation varies from 16% to 40%, with a higher frequency occurring in patients below 50 years (40-57%) and in patients older than 50 years (55-70%), in whom misdiagnosis and delayed diagnosis are common. Complications occur in 1-5% of patients with appendicitis. Postoperative wound infections account for almost one third of the associated morbidity [1, 6, 7] .
PSP is a secretory protein produced predominantly in the pancreas and the gut. There is evidence from experimental and clinical trials that the levels of PSP in the blood increase in the presence of inflammation or infection [8, 9] . However, it is still unknown whether PSP is superior to other established blood tests (e.g. WBC or CRP) in predicting appendicitis in patients presenting with abdominal pain and a clinical suspicion of appendicitis at the emergency room.
The objective of this trial is to 1) determine the diagnostic accuracy of PSP in predicting acute appendicitis and 2) compare PSP with other established markers used in the diagnostic work-up.
Methods/design
The PSP Appendix Trial is a prospective, multi-center, cohort study to assess the value of PSP in the diagnostic workup of acute appendicitis. Two hundred and forty five patients will be recruited. Interim analysis will be performed once 123 patients are recruited [Additional file 1]. A power analysis will be performed on the actual and precise data collected. At interim analysis the potential need to modify the sample size will be investigated. If any changes are suggested by the external data monitoring committee, the principal investigators will decide on the feasibility of the potential changes and submit a formal addendum to the ethics committee. No changes will be made to the protocol or study design unless first approved by the ethics committee. Any changes to the protocol approved by the ethics committee will be updated at clinicaltrials.gov [NCT01610193] .
Study objectives
The primary endpoint of the study is histopathological diagnosis of appendicitis on the specimen after appendectomy in order to assess the diagnostic accuracy of PSP calculated in predicting acute appendicitis. Secondary endpoints concern:
1. Grade of appendicitis detected intraoperatively: G0: Appendix without any abnormalities detected introperatively G1: Acute appendicitis G2: Gangrenous appendicitis G3: Perforated or phlegmon G4: Periappendicular abscess 2. Alvarado Score elements which are obtained from the patient's history, the physical examination and from laboratory tests. A score below 5 is strongly against a diagnosis of appendicitis, while a score of 7 or more is strongly predictive of acute appendicitis.
In patients with an equivocal score of 5 or 6, a CT scan is used to further reduce the rate of negative appendectomy [10] . 3. Pancreatic Stone Protein (PSP) blood serum/ plasma levels will be correlated with this score. Surgical complications defined according to the Clavien-Dindo Classification will be monitored [11] .
Inclusion criteria
-All patients that will present at the emergency department with abdominal pain and a clinical suspicion of acute appendicitis: -Age >18 years of age -Clinical suspicion of appendicitis as the primary or differential diagnoses -Patients able to provide informed consent [12] . Once a patient is assessed for eligibility and is found to meet the inclusion criteria, the patient should immediately enter the trial before any investigations have ordered blood tests, imaging, etc. The consent forms and patient information have to be provided to the patient. If the patient does not agree to participate in the trial, this should be documented in the online CTMS. If the patient agrees to participate in this trial, blood has to be taken for Pancreatic Stone Protein (PSP) measurement (1 tube of 5-10 ml, for serum determination in clinical chemistry). This tube has to be labelled as B1 followed by the patient trial number (B1_II_YYYY). The letter "B" stands for blood" and "1" as the first blood collection. The patient trial number should be the name initials (II) followed by the year of birth (YYYY). As part of the standard care, blood has to be taken for analysis for full blood count and CRP measurement at participating institutions. In particular, the White Blood Cell Count (WBC), Neutrophil Granulocytes (%) and C-reactive Protein (CRP) will have to be entered into the CTMS. The blood has to be taken at the same time for PSP, WBC and CRP as soon as the patient signs the consent form while still at the emergency department. A pregnancy test (beta hCG) has to be also performed and information entered into the CTMS. The investigators are free to perform any other blood tests deemed necessary.
The investigators are free to use any kind of imaging as part of the routine management of patients. Ultrasound Scan (USS) or Computed Tomography (CT) data will be entered in the CTMS.
The physician will then decide whether the patient should be subject to further diagnostics, referred to another inpatient or outpatient department or be discharged home [Additional file 4]. If the patient is admitted for an operation, this has also to be documented in the CTMS. If the physician decides to take blood to assess the progress of the patient before an operation or discharge, an additional tube for PSP measurement is taken (see above). This tube has to be labelled as (B2_II_YYYY, e.g. B2_DR1978, see example above, "2" stands for second blood test for PSP). The same centrifugation process has to be performed to sample B2 as for B1.
Then the investigators will be asked to indicate the type of the operation and the intra-operative findings, if the patient was operated. During hospitalisation, the physician should document any complication according to the Clavien-Dindo Classification of surgical complications. For the patients that were operated, the physician will need to document the date of discharge. Once the histopathology report of the resected specimen has been received, the diagnosis will be entered in the CTMS. To ensure standardized reporting, all centers will adhere to the above classification of appendicitis.
Continuous variables will be compared with the Student t, Mann-Whitney U, one-way ANOVA, and Kruskal-Wallis tests, where appropriate. Differences among proportions derived from categorical data will be compared using the Fischer's Exact or the Pearson χ 2 tests, where appropriate. All p values will be two-sided and considered statistically significant if p ≤ 0.05. Sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), negative likelihood ratio (NLR), Yuden's index (YI), diagnostic odds ratio (OR), and the receiver operator characteristic (ROC) curve will be calculated. Data will be presented as mean (SD), median (i.q.r.) and Odds Ratios (95% CI) where appropriate. Reproducibility of PSP measurements will be performed by duplicating the samples and the variability assessed by the Pearson's Correlation Coefficient. Statistical analysis will be performed using SPSS Statistics version 20 (SPSS: An IBM Company, Chicago IL, 2011).
